Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-822-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees24
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions
What is Kezar Life Sciences' stock symbol?
Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."
How were Kezar Life Sciences' earnings last quarter?
Kezar Life Sciences Inc (NASDAQ:KZR) issued its earnings results on Wednesday, August, 7th. The company reported ($0.46) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.02. View Kezar Life Sciences' Earnings History.
When is Kezar Life Sciences' next earnings date?
What price target have analysts set for KZR?
3 Wall Street analysts have issued 12-month target prices for Kezar Life Sciences' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate Kezar Life Sciences' stock price to reach $15.00 in the next year. This suggests a possible upside of 324.9% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.
What is the consensus analysts' recommendation for Kezar Life Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.
Has Kezar Life Sciences been receiving favorable news coverage?
News articles about KZR stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kezar Life Sciences earned a news impact score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Kezar Life Sciences.
Are investors shorting Kezar Life Sciences?
Kezar Life Sciences saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 900,800 shares, an increase of 8.0% from the August 30th total of 834,300 shares. Based on an average trading volume of 78,700 shares, the short-interest ratio is currently 11.4 days. Approximately 7.7% of the shares of the stock are sold short. View Kezar Life Sciences' Current Options Chain.
Who are some of Kezar Life Sciences' key competitors?
Some companies that are related to Kezar Life Sciences include Cyclerion Therapeutics (CYCN), Geron (GERN), Dynavax Technologies (DVAX), Molecular Templates (MTEM), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), BIOFRONTERA AG/ADR (BFRA), ProQR Therapeutics (PRQR), Puma Biotechnology (PBYI), Forty Seven (FTSV), resTORbio (TORC), Seres Therapeutics (MCRB), Xeris Pharmaceuticals (XERS), MannKind (MNKD) and Provention Bio (PRVB).
What other stocks do shareholders of Kezar Life Sciences own?
Who are Kezar Life Sciences' key executives?
Kezar Life Sciences' management team includes the folowing people:
- Mr. John Fowler, Co-Founder, CEO & Director (Age 47)
- Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)
- Dr. Jack Taunton, Co-Founder
- Mr. Marc L. Belsky, CFO & Sec. (Age 64)
- Michael Wolfe, Director of Fin. & Operations
When did Kezar Life Sciences IPO?
(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.
How do I buy shares of Kezar Life Sciences?
Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kezar Life Sciences' stock price today?
One share of KZR stock can currently be purchased for approximately $3.53.
How big of a company is Kezar Life Sciences?
Kezar Life Sciences has a market capitalization of $67.56 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.
What is Kezar Life Sciences' official website?
How can I contact Kezar Life Sciences?
Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]
MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)
MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days.
